Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Non-Hodgkin Lymphoma
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
October 28th, 2008
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free survival. A companion editorial discussed the growing evidence for the efficacy of radioimmunotherapy (RIT) in B-cell lymphomas. Cell Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Source: Cancer Weekly (2008-10-28)
|
